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Abstract 44 
Cytomegalovirus (CMV) infection sometimes causes large expansions of CMV-specific 45 
T-cells, particularly in older people. This is believed to undermine immunity to other 46 
pathogens and to accelerate immunosenescence. While multiple different CMV proteins 47 
are recognized, most publications on age-related T-cell expansions have focused on 48 
dominant target proteins, UL83 or UL123, and the T-cell activation marker, IFN-. We 49 
were concerned that this narrow approach might have skewed our understanding of 50 
CMV-specific immunity at older ages. We have, therefore, widened the scope of 51 
analysis to include in vitro-induced T-cell responses to 19 frequently recognized CMV 52 
proteins in young and older healthy volunteers and a group of oldest old, long-term 53 
survivors (>85 years of age). Polychromatic flow-cytometry was used to analyze T-cell 54 
activation markers (CD107, CD154, IL-2, TNF, IFN-) and memory phenotype (CD27, 55 
CD45RA). The older had on average larger T-cell responses than the young, but, 56 
interestingly, response size differences were relatively smaller when all activation 57 
markers were considered rather than IFN- or TNF alone. The oldest old recognized 58 
more proteins on average than the other groups and had even bigger T-cell responses 59 
than the older with a significantly larger central memory CD4 T-cell component. (191 60 
words)  61 
  62 
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Introduction 63 
T-cells have a central role in containing virus infections and T-cell immunity to CMV has 64 
been repeatedly characterized [1-4]. As aged T-cells die, the thymus gland replenishes 65 
the T-cell pool with fresh, naïve cells, but thymic output is reduced by 90% in 20 year-66 
olds, and by 99% in 70 year-olds, compared to newborns [5].  However, T-cell numbers 67 
do not decline significantly as we age because memory T-cell proliferation compensates 68 
the lack of fresh naïve cells. 69 
Cytomegalovirus (CMV) infection is uniquely effective in driving compensatory memory 70 
T-cell proliferation; other herpes viruses have been implicated in this process to a much 71 
lesser degree [6, 7]. Frequent reactivation of latent CMV is thought to repetitively 72 
stimulate the T-cell compartment, driving up its size over time [8]. Very large CMV-73 
specific T-cell responses observed in older people have created the paradigm of CMV-74 
induced T-cell ‘memory inflation’ [9]. Some researchers suspect that these T-cell 75 
expansions undermine immune responsiveness by skewing the T-cell receptor 76 
repertoire towards CMV [2, 10, 11]. However, the studies exploring the relationship 77 
between immunosenescence and the size of the CMV-specific T-cell response in 78 
humans to date have considered a limited number of recognized target proteins. By 79 
focusing on specific proteins or even individual epitopes and single functions (e.g. IFN-80 
) they have created a fragmented picture of CMV specific T-cell immunity in older life 81 
[10-16].  82 
We intended to assess whether CMV infection leads to a large increase of CMV-specific 83 
T-cells in older people by measuring T-cell responsiveness to a wider, more 84 
representative range of proteins than previously studied and also including several 85 
functional response read-outs. We used protein-spanning peptide pools for CMV 86 
antigen-specific stimulation [17-23]. Target protein selection was based on our previous 87 
work showing that the full size of the response to CMV (represented by 213 protein-88 
spanning peptide pools) can be extrapolated from the responses to 19 proteins, 89 
including 6 dominant CD4 and 15 dominant CD8 T-cell targets [24].  90 
The increase of T-cell response size was smaller in the CD8 but larger in the CD4 91 
compartment in older compared to young participants than previously reported. In 92 
addition, our analysis of response breadth and T-cell memory compartments across all 93 
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protein-specific responses provides new insight into the changes that occur in older 94 
people and a potential signature of successful ageing.   95 
96 
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Methods 97 
Ethics statement 98 
This study was approved by the UK National Research Ethics Service (NRES) 99 
(09/H1102/84) and the University of Parma Ethics Committee. Written informed consent 100 
was obtained from all participants. The study was conducted in agreement with the 101 
Declaration of Helsinki. 102 
 103 
Participants 104 
Fifty-five healthy volunteers referred to as ‘young’ (19-35 years, including university 105 
students and staff) and 131 healthy volunteers referred to as ‘older’ (60-85 years, 106 
recruited by general medical practitioners) were recruited in Brighton (UK). Twenty-two 107 
additional individuals, referred to as ‘oldest old’ (85-102 years) with known T-cell 108 
responsiveness to CMV were recruited at Parma University Hospital (Italy) as a 109 
comparison group of particularly advanced age. Exclusion criteria were designed to 110 
select generally healthy young and older individuals but in the oldest old the presence of 111 
cerebrovascular and/or cardiovascular disease (heart failure, TIA, AMI) was accepted, 112 
as this is representative of such an advanced age. Details of all inclusion/exclusion 113 
criteria and demographics for CMV- participants are provided in the online supplement. 114 
Demographics for CMV+ participants are shown in Table 1. Venous blood was collected 115 
in sodium-heparin plasma tubes (BD, Oxford, UK). Only CMV+ individuals (52.6% of the 116 
older and 47.3% of the young participants) were selected for the analysis of CMV-117 
specific T-cell responsiveness. The proportion of Non-White among young participants 118 
ranged from 20-33%, depending on the analysis. There were no statistically significant 119 
differences between White and Non-White British participants with respect to response 120 
size distribution. 121 
 122 
CMV serology 123 
CMV IgG serology (Architect CMV IgG, Abbot, Maidenhead, UK) was performed at the 124 
Brighton and Sussex University Hospital Trust (BSUHT) virology laboratory.  125 
 126 
Peripheral blood mononuclear cell (PBMC) Isolation and activation 127 
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PBMCs were isolated by density gradient centrifugation (Ficoll-Hypaque, PLUS 128 
Healthcare, Buckinghamshire, UK) as described previously [25]. PBMCs were 129 
resuspended at 5x106 cells/mL in complete RPMI (Fisher Scientific, Loughborough, UK) 130 
containing 10% fetal calf serum (Fisher). For each tube 200 μL of PBMC suspension 131 
was incubated with peptide pools dissolved in DMSO (Sigma-Aldrich, Gillingham, UK), 132 
DMSO alone as a negative control, or Staphylococcus enteroxin B (SEB, Sigma) as a 133 
positive control, and Monensin (BD) for 2 hours in a standard incubator (37°C, 134 
humidified 5% CO2 atmosphere) before addition of BFA (Sigma) for the remaining 135 
incubation time of 14 hours.  More details are provided in the online supplement. 136 
 137 
CMV Peptide Pools  138 
Peptides (15 amino acids length, 11 amino acids overlap between adjacent peptides) 139 
spanning the entire amino acid sequence of 19 CMV proteins were prepared by solid-140 
phase synthesis using the same protein sequences as previously published [24]. Quality 141 
control included mass spectroscopy and HPLC. Peptide purity was generally >80%. 142 
One peptide pool per protein was generated (‘Pepmix’, JPT Peptide Technologies, 143 
Berlin, Germany) save for UL48, for which two pools were required. Pools were 144 
arranged in 16 stimulation pools, of which 12 contained one protein (frequent 145 
responses) and 4 contained 2 proteins each (as they elicited less frequent responses) 146 
(Table 2). Freeze-dried pools were stored at -80°C. 147 
 148 
Antibodies and cell staining  149 
We used the following fluorescence-conjugated monoclonal antibodies; anti-CD3-v500, 150 
anti-CD8-Allophyocyanine(APC)-H7, anti-CD27-Phycoerythrine(PE), IL-2-Fluoresceine-151 
iso-thio-cyanate(FITC), TNF-α- Alexa 700, CD107a-APC (all BD Biosciences, Oxford, 152 
UK), anti-CD4-Peridinin chlorophyll(PerCP), anti-IFN- PE-Cy7(Cyanine 7), anti-CD154 153 
Pacific-Blue (BioLegend, Cambridge, UK), anti-CD45RA-ECD (Beckman Coulter, UK) 154 
and Yellow live-dead stain (Invitrogen, Paisley, UK). Cells were stained on the surface 155 
and intracellularly as described previously [25] (see online supplement for details).  156 
 157 
Data analysis and gating strategy 158 
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FlowJo-v9.x software (TreeStar Inc., Ashland, USA) was used for analysis. After 159 
identifying CD4 and CD8 T-cells, individual gates were set on activation marker-positive 160 
events (Supplementary Fig. S1) and then combined using FlowJo’s Boolean gate 161 
function. All subset frequencies were computed based on the frequencies of individual 162 
non-overlapping Boolean subsets after background subtraction. Responses were 163 
considered positive if they were identifiable by at least one activation marker, formed a 164 
visible cluster on inspection, and included ≥ 0.01% (1/10,000 T-cells) of the reference 165 
population. The analysis of target protein recognition profiles and total CMV-specific 166 
responses excluded participants whose responses had not been tested with the 167 
complete set of 19 peptide-pools (e.g. for lack of sufficient material). 168 
 169 
Absolute T-cell counts 170 
Absolute T-cell counts (cells/nL of whole blood) were determined in most, but not all, UK 171 
participants. They  were computed by multiplying the percentage of CD3 T-cells among 172 
white blood cells with the white blood cell count (wbc) obtained with a Sysmex Counter 173 
(Sysmex, UK) (see online supplement for details). 174 
 175 
T-cell polyfunctionality 176 
The polyfunctionality index was calculated as previously described [26] (see online 177 
supplement for details). 178 
 179 
Statistical analysis 180 
SPSS v22 software (IBM, London, UK) was used for statistical analyses. The Chi-181 
square test was used to compare protein recognition between cohorts. Histograms, Q/Q 182 
plots, and the Kolmogorov-Smirnov test were used to determine data distribution. Non-183 
parametric tests (Mann-Whitney) were used to compare groups. T-cell frequencies were 184 
log-transformed where appropriate for normalizing distribution or improving data 185 
presentation. P-values ≤0.05 were considered significant for single endpoints. Multiple 186 
end-point correction (Bonferroni) was applied when appropriate (p≤0.05/n, where n is 187 
the number of endpoints).   188 
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Results 189 
T-cell response size is unrelated to protein recognition frequency 190 
Size and phenotype of T-cell responses to 19 CMV proteins were analyzed in young, 191 
older, and oldest old participants (Table 1). Activated T-cells were quantified using five 192 
simultaneous read-outs, IL-2, IFN-, TNF, CD107a and CD154. As previously reported, 193 
the average size of the T-cell response to a given CMV protein was unrelated to the 194 
proportion of individuals recognizing it (Fig. 1A-B) [24].  195 
 196 
CMV-specific T-cell response breadth is increased in the oldest old 197 
The frequencies of T-cells recognizing specific target proteins were not significantly 198 
different between young and older participants, however, significant differences existed 199 
between the older and oldest old with respect to several proteins (Fig. 2A). The number 200 
of target proteins recognized per individual seemed somewhat bigger in the older 201 
compared to the young participants but this was not statistically significant. However, 202 
the oldest old had significantly broader responses than the older participants (Fig. 2B). 203 
The oldest old were considered examples of exceptional ageing and compared only 204 
with the older whose age was within normal expectation (direct comparisons between 205 
the oldest old and the young did not appear useful). 206 
 207 
The median frequency of CMV-specific TNF-producing CD4 T-cells is 4.9 times 208 
higher in older than young participants 209 
We initially compared responses between young and older participants as this was 210 
considered to reflect average ageing. As a global measure of T-cell responsiveness to 211 
CMV, without bias to selected proteins, we first compared the summed response to the 212 
19 proteins (‘total response’) among CD4 and CD8 T-cells and then the responses to 213 
the two most frequently recognized proteins for CD4 (UL83, UL55) and CD8 T-cells 214 
(UL83, UL123) (Fig. 3). Response size comparisons were based on the combined 215 
readout (cells were considered activated if at least one activation marker was positive), 216 
IFN- alone (the most commonly used T-cell activation marker) or TNF alone. The 217 
difference of the total CD4 T-cell response between the young and the older (Fig. 3A) 218 
was statistically significant only when IFN-or TNF were considered alone, but not 219 
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when the combined read-out was used. In older participants, the median of the total 220 
CD4 T-cell response was 3.2, 4.5, and 4.9-fold higher than in the young group for the 221 
combined read-out, IFN-, and TNF, respectively. UL83-specific responses were 222 
significantly larger in the older group for each of the read-outs; unlike UL55-specific 223 
responses, which were not significantly different for any read-out. In CD8 T-cells a 224 
similar pattern was observed but increases were generally smaller (Fig. 3B). Medians 225 
for the total CD8 T-cell response were 2.1, 2.3, and 2.3-fold higher in the older than in 226 
the young group for the combined read-out, IFN-, and TNF, respectively. CD8 T-cell 227 
responses to UL83 were also significantly larger in older compared with young 228 
participants (any read-out), but no significant difference was observed with respect to 229 
UL123 (‘IE-1’).  230 
Interestingly, total response size differences (all 19 proteins) between the oldest old and 231 
the older (aged 85-103) were significant for all read-outs for both CD4 and CD8 T-cells 232 
(Fig. 3A-B, left). This might be explained in part by the higher average number of 233 
proteins recognized in the oldest old (Fig. 2B). For both CD4 and CD8 T-cells, UL83-234 
specific responses were also significantly different between these groups for the 235 
combined read-out and IFN- but not TNF. The UL55-specific CD4 T cell response was 236 
significantly higher in the oldest old group using the combined read out. No direct 237 
comparison between oldest old and young participants was made.  238 
 239 
Absolute T-cell counts may conceal the increasing CMV bias of the T-cell 240 
repertoire in the older  241 
The corresponding response size differences in terms of absolute T-cell counts (cells/nL 242 
of blood) between young and older participants were less conspicuous and statistically 243 
significant only for UL83-specific CD4 T-cells (Supplementary Fig. S2A-B). At the 244 
same time a general decline of CD4 and, particularly, CD8 T-cell numbers (statistically 245 
significant) was observed in the older group (Supplementary Fig. S2C-D). Absolute T-246 
cell counts, therefore, underestimated age-related increases in CMV-specific response 247 
dominance that were, however, revealed by the CMV-responsive fractions of CD4 or 248 
CD8 T-cells (Fig. 3A-B). Absolute T-cell counts were not available for the oldest old.  249 
 250 
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CMV-specific CD4 T-cells arise predominantly from the TEM compartment in 251 
young and older but from the TCM compartment in the oldest old 252 
The distributions of CMV-specific CD4 and CD8 T-cells among the memory 253 
compartments defined by CD45RA and CD27 expression were evaluated in all 254 
individuals (CD45RA+/CD27+ = ‘naïve’ or TNA; CD45RA-/CD27+ = ‘central memory’ or 255 
TCM; CD45RA-/CD27- = ‘effector memory’ or TEM; CD45RA+/CD27- = ‘revertant’ or 256 
TEMRA) (Supplementary Fig. S3A). This distribution changes subject to age and CMV-257 
status (Supplementary Fig. S3B) [27], and in CMV+ individuals is also related to the 258 
size of CMV-specific T-cell responses [28]. The quantitative contribution of these 259 
compartments to the total CMV-specific T-cell response was determined across all 19 260 
target proteins. In young and older participants, the largest proportion of the CD4 T-cell 261 
response arose from the TEM compartment (Fig. 3C), whereas in CD8 T-cells an equally 262 
large or even larger contribution originated from the TEMRA compartment (particularly in 263 
the older) (Fig. 3D). Surprisingly, in the oldest old, among CMV-specific CD4 T-cells, 264 
the TCM compartment was dominant (Fig. 3C). Note that differences between the sizes 265 
of corresponding memory compartments in different age groups in Fig. 3C-D (for 266 
example the CD4 TCM compartment in the older versus the oldest old participants) 267 
reflect the overall response size differences between these age groups and show to 268 
what extent these differences are located in each memory compartment. However, 269 
relative changes of the contribution that each memory compartments makes to the 270 
whole response (i.e. all four compartments together) are more easily appreciated when 271 
frequencies are normalized, in which case a significant increase is visible for oldest old 272 
versus older participants in the CD4 TCM compartment and a significant decrease in 273 
older compared with young participants in the CD8 TNA compartment (Supplementary 274 
Fig. S4A). T-cell memory compartment distributions were also expressed in absolute 275 
counts (limited to young and older participants) showing a very similar pattern as when 276 
expressed as fractions of CD4 or CD8 T-cells (supplementary Fig. S4B).  277 
 278 
The entire CD4 and CD8 T-cell memory compartments (irrespective of antigen 279 
specificity) also showed larger central memory components in the oldest old than the 280 
older but differences were not significant. The most striking difference compared with 281 
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CMV-specific T-cells alone was the much smaller relative size of the TEMRA 282 
compartment. In older participants, the TEMRA compartment dominated the CD8 T-cell 283 
repertoire whereas in the oldest old the TEM compartment was dominant 284 
(Supplementary Fig. S4C, top and bottom). 285 
 286 
We finally tested T-cell polyfunctionality across the memory compartments; it was 287 
generally highest in the TEM compartment in CD4 and CD8 T-cells in all three groups, 288 
however, in the oldest old, despite a general decline of polyfunctionality, the CD8 TNA 289 
compartment was more polyfunctional than in older participants (Supplementary Fig. 290 
5). 291 
  292 
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Discussion 293 
Our study explored whether the CMV-specific T-cell response is generally inflated in 294 
older people. It provides a more definitive answer than previous work, which has 295 
focused on select antigens, individual peptides/MHC-multimers, and often single 296 
effector read-outs. While CMV-specific T-cell responses were on average larger in older 297 
than in young people, our data provides compelling evidence that the size of such 298 
differences depends strongly on how the comparison is made; be it with respect to 299 
individual proteins, or a range of proteins, be it with respect to single activation markers, 300 
or a combination of activation markers. Response size differences were more 301 
pronounced when the analysis was focused on single effector read-outs (IFN- TNF), 302 
but less striking when all read-outs were considered simultaneously. This demonstrates 303 
that differences in functional profiles between individuals, or groups of individuals, may 304 
appear as differences in response size if single activation markers are used as read-out.  305 
While 2.1-fold and 3.2-fold higher median frequencies of CMV-specific CD8 and CD4 T-306 
cells, respectively, in older compared to young people (considering all T-cell targets and 307 
read-outs) clearly show a considerable age-related response size increase, it remains 308 
unclear if this is enough to significantly undermine immunity in older people. An 309 
increase of CMV-specific pro-inflammatory T-cells, however, might have a more 310 
profound effect on the immune system. When considering TNF-producing T-cells only, 311 
the difference between young and older was ‘only’ 2.3 fold for CD8 T-cells but, 312 
surprisingly, 4.9 fold for CD4 T-cells (a similar pattern was seen for IFN- producing T-313 
cells). It appears, therefore, that the effect of ageing (within normal bounds) on CMV-314 
specific T-cell numbers has been somewhat overestimated with regard to the CD8 but 315 
underestimated with respect to the CD4 compartment. In any case, our work has 316 
clarified that a huge increase in TNF-producing CMV-specific T-cells does indeed occur 317 
in the average CMV+ older person.  318 
Pourgheysari et al. previously reported significant expansions of CMV-specific CD4 T-319 
cells in older people, however, using a CMV lysate for stimulation. Based on TNF 320 
production they found a little more than a doubling in older compared to younger 321 
people, which is less than half the difference found in the present study. This 322 
discrepancy could be explained, first, by the fact that the ‘young’ people examined by 323 
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Pourgheysari were up to 50 years old compared with up to 35 years in our study, and 324 
second, that CMV lysate (made from CMV-infected fibroblasts) does not stimulate T-325 
cells as effectively as protein-spanning peptide pools [24].  326 
 327 
The oldest old represented a group of exceptional, successfully aged people. They 328 
recognized more proteins on average than the older participants (see Fig. 2B) and their 329 
summed responses to all proteins were much larger, irrespective of read-out. Future 330 
research will determine whether increased response breadth contributes to successful 331 
ageing, is a by-product of it, or possibly the result of lifestyle factors contributing to 332 
longevity. Interestingly, the role of UL83 as an unusual protein in regards to driving 333 
CMV-specific T-cell expansions was confirmed by the observation of an even larger 334 
difference in response size between the oldest old and older than between the older 335 
and the young. Whether very large UL83-specific T-cell responses are harmful, helpful, 336 
or maybe neither, remains unclear. Unlike the young and older, who were 337 
predominantly White British, the oldest old were White Italian. Both population samples 338 
belong to the same major ethnicity (Caucasoid), however, the frequencies of some HLA 339 
alleles vary between UK and Italian populations according to the online HLA-allele 340 
database, www.allelefrequencies.net [29]. It may be that HLA-type or other genetic 341 
factors have affected response breadth and/or size somewhat but it is very unlikely that 342 
they would explain the full extent of the differences we have observed.  343 
 344 
By quantifying the contribution of the different T-cell memory compartments to the 345 
overall CMV-specific response in a summative way across all 19 target proteins, our 346 
study significantly extends previous reports [10, 28, 30]. This comprehensive evaluation 347 
demonstrated that both in young and older participants the bulk of the CMV-specific T-348 
cell response arises from the TEM compartment in CD4 T-cells, and to a similar extent 349 
from the TEM and TEMRA compartments in CD8 T-cells. In the oldest old ‘survivors’, 350 
however, a large contribution to the CD8 T-cell response size and the largest 351 
contribution to the CD4 T-cell response size originated from the TCM compartment. This 352 
raises the question, does an increase of this compartment occur as a result of 353 
successful ageing or is it a survival advantage during the process of ageing? The latter 354 
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would support the idea that a long-lived TCM pool provides improved protection from 355 
infection as a result of its ability to proliferate upon antigen re-exposure [31]. 356 
Interestingly, it was recently shown that the live attenuated VZV vaccine, Zostavax, 357 
boosts polyfunctional central memory CD4 T-cells in individuals aged 55-65 [32]. It is, 358 
therefore, tempting to speculate that expansion of the TCM compartment both in terms of 359 
CMV-specific T-cells, but also generally, reflects natural boosting by exposure to real 360 
infections. However, this observation and potential consequences for vaccine design 361 
would need to be assessed in future studies.  362 
Importantly, the definition of T-cell memory compartments by CD45RA versus CD27 363 
expression is not precise, e.g. T-cells in the naïve compartment would not be expected 364 
to produce IFN- after overnight stimulation, indicating a more advanced phenotype. 365 
Nonetheless these, and similar subset definitions based on two markers (e.g. CD45RA 366 
and CCR7) provide good overall subset discrimination and are widely used in the field 367 
[28, 33]. Interestingly, stem cell memory T-cells (TSCM) are antigen-experienced and, like 368 
naïve cells, express CD45RA and CD27. It is possible, therefore, that the oldest old, 369 
have accumulated CMV-specific TSCM [34] potentially contributing to protection.  370 
Using the same cohorts, we recently reported that polyfunctionality was on the whole 371 
reduced in the oldest old [35], however, we did not examine differences between T-cell 372 
memory subsets. Our current analysis confirmed that polyfunctionality in the oldest old 373 
is generally lower than in older individuals but also showed a slight increase of 374 
polyfunctionality in CD8 TNA cells. This agrees with a recent report by others showing 375 
increased polyfunctionality among CD8 TNA (but, interestingly, not TSCM) cells in an older 376 
compared to a younger participant group [36]. Age-wise, this older group was in 377 
between our older and oldest old groups.  378 
 379 
Importantly, our present work shows that age-related expansions of the CMV-specific T-380 
cell response can only be fully appreciated if a representative range of proteins and 381 
several functional read-outs are considered in combination, allowing an assessment of 382 
response breadth both in regards to target proteins and functionality. We also previously 383 
demonstrated striking differences between individuals regarding CMV protein 384 
dominance and response hierarchies [37], providing additional reason to use many 385 
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target proteins in parallel for this kind of work. In conclusion, our current and previous 386 
findings combined suggest that a possible ‘signature’ of successful ageing might include 387 
a broad CMV-specific T-cell response with a large central memory component but 388 
overall moderate polyfunctionality (thus avoiding unnecessary ‘collateral’ tissue 389 
damage) [35]. We believe that our work will be useful in informing the design of future 390 
studies in this field. 391 
  392 
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Figure Legends 494 
 495 
Fig. 1. The frequency of target protein recognition is unrelated to T-cell response 496 
size. PBMC from CMV+ participants were stimulated overnight with 19 CMV protein-497 
derived overlapping peptide-pools. Activated T cells were identified by flow-cytometry. 498 
(A) Bars represent all age groups and indicate the fraction of individuals recognizing 499 
individual proteins with respect to CD4 and CD8 T-cells. Proteins are ordered by 500 
decreasing frequency of recognition. (B) The sizes of CD4 and CD8 T-cell responses 501 
(Log10 transformed fractions) across all age groups are shown for all proteins in the 502 
same order as under (A).  503 
 504 
Fig. 2. The breadth of the CMV-specific T-cell response is not significantly 505 
different between young and older participants but strongly increased in the 506 
oldest old. PBMC from CMV+ participants were stimulated over night with 19 CMV 507 
protein-derived overlapping peptide-pools. Activated T cells were identified by flow-508 
cytometry. (A) A comparison of response breadth between the young (white bars) and 509 
older (grey bars) individuals revealed no significant differences in terms of protein 510 
recognition frequencies (CMV proteins are ordered by decreasing frequency of 511 
recognition in the older group), however, there were several significant differences 512 
between the older and the oldest old (dark grey bars) (Bonferroni multiple end-point 513 
correction, significance threshold set to p=0.003, significant differences indicated by 514 
asterisks). (B) The number of recognized CMV target proteins (between 1 and 15) was 515 
computed separately for CD4 and CD8 T-cells in the young (left) and older (middle), 516 
and oldest old (right), suggesting a mild (non-significant) trend for higher response 517 
counts in older compared to young participants, but showing a significant difference 518 
between older and oldest old. Cross-bars show median and interquartile range. 519 
 520 
Fig. 3. Age-related increases in T-cell response size depend on target protein-521 
specificity and functional response read-out. PBMC from CMV+ participants were 522 
stimulated over night with 19 CMV protein-derived overlapping peptide-pools. Activated 523 
T cells were identified by flow-cytometry. While our study focused on ‘average’ ageing, 524 
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i.e. differences between young and older participants, oldest old participants are shown 525 
as examples of unusually succesful ageing. (A, B) The fractions of all cells displaying at 526 
least one activation marker (‘combined read out’), IFN-, or TNF are shown. Diagrams 527 
show the CMV-specific T-cell response size (log-transformed fractions of CD4 or CD8 528 
T-cells) for all 19 proteins combined (left panels) and the most frequently recognized 529 
CMV proteins in the UK cohort (A) for CD4 T-cells with respect to UL83 (middle) and 530 
UL55 (right), (B) for CD8 T-cells with respect to UL83 (middle) and UL123 (right). 531 
Statistical significance levels are indicated. The main study end-point was the increase 532 
in CMV-specific T-cell response size between young and older people (combined read-533 
out in connection with all 19 proteins); the significance level of p≤0.05 was not adjusted. 534 
(C,D) T-cell memory compartment distributions defined by the expression of CD27 and 535 
CD45RA (CD45RA+/CD27+ = ‘naïve’ or TNA; CD45RA-/CD27+ = ‘central memory’ or 536 
TCM; CD45RA-/CD27- = ‘effector memory’ or TEM; CD45RA+/CD27- = ‘revertant’ or 537 
TEMRA) showed significant differences between young and older participants among 538 
CMV-specific TCM CD4 T-cells and CD8 revertant (TEMRA) T-cells. Compared with older 539 
participants, the oldest old displayed a striking and significant increase of the CD4 540 
central memory (TCM) compartment (Mann-Whitney test, significance threshold set to at 541 
p≤0.0125, Bonferroni correction for 4 end-points). No direct comparison was made 542 
between the young and oldest old participants. Boxplots show minimum, maximum, 543 
median, interquartile range, and outliers (“o”). 544 
545 
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 Tables 546 
 547 
Table 1. CMV+ participant demographics 548 
Parameter  ‘young’  ‘older’  ‘oldest old’ 
Total n 26 69 22 
Age range (mean ± STD) 19 – 35 
(23.3±4.2) 
60 – 85 
(69.0±7.5) 
85-103 
(95.9±5.9) 
Females 18 (69 %) 35 (51 %) 16 (73%) 
Males 8 (31 %) 34 (49 %) 6 (27%) 
White (British or Italian) 18 (69%) 69 (100 %) 22 (100%) 
Non-White Britisha 8 (31%) 0 (0%) n.a. 
aNon-white British young adults included 1 Syrian, 2 Indian, 1 Sri-Lankan, 549 
1Bangladeshi, 1 Malaysian, 1 White/Asian and 1 Black African/Asian participants. 550 
 551 
 552 
 553 
  554 
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Table 2: CMV peptide-pools used for stimulation 555 
Protein(s) No. of Peptides 
UL55 224 
UL83 138 
UL86 340 
UL122 120 
UL123 143 
UL99 45 
UL153 67 
UL32 260 
UL28 92 
UL48Aa 281 
UL48Ba 281 
US3 44 
UL151& UL82 219 (82 &137) 
UL94 & US29 197 (84 &113) 
UL103 & 
US32 
103 (60 & 43) 
US24 & UL36 240 (123 &117) 
a UL48 was divided into two pools (UL48A and UL48B), however, results were combined 556 
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CMV-specific T-cell responses at older ages: broad responses with a large central 3 
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Materials and Methods 23 
 24 
Participants 25 
Inclusion criteria for UK donors: age 20-35 or 60-85 years; exclusion criteria were  26 
known immunodeficiency (including HIV-infection), organ transplantation, use of 27 
immunosuppressive or immune-modulating drugs within the last year (excluding 28 
acetylsalicylic acid ≤ 100mg/day), cancer or treatment for cancer within the previous 5 29 
years, insulin dependent diabetes, moderate or advanced renal failure, liver disease, 30 
endocrine disorders (except corrected thyroid dysfunction), autoimmune disease, 31 
dementia/mental incompetence, alcohol/other drug abuse, acute infection or illness in 32 
the last 4 weeks, raised body temperature (>37.5C).  33 
 34 
Inclusion criteria for Italian volunteers: minimum age 85 years, known CMV 35 
responsiveness; exclusion criteria were evidence of endocrine (except thyroid 36 
dysfunction), autoimmune and neoplastic diseases, acute infections or illness in the last 37 
2 months, renal or liver failure, and use of immune-modulatory medications (including 38 
steroids, non-steroidal anti-inflammatory agents, acetylsalicylic acid >100mg/day, or 39 
immunosuppressive drugs). 40 
 41 
Peripheral blood mononuclear cell (PBMC) Isolation and activation 42 
Twenty-five μg per peptide of CMV peptide-pools (“PepMix”, JPT Peptide Technologies, 43 
Berlin, Germany) was dissolved in 100 μL of dimethyl-sulfoxide (DMSO, Sigma-Aldrich, 44 
Gillingham, UK). Two μL of peptide solution, 1.5 μL of anti CD107a (BD) and 0.5 μL of 45 
  3
Monensin (BD) were added to 46 μL of complete media and placed in 4.5 mL 46 
polystyrene tubes (BD). After the addition of 200 μL of PBMC suspension the tubes 47 
were incubated at 37°C in a standard incubator with a humidified 5% CO2 atmosphere. 48 
After 2 hours, 1 μL of Brefeldin A (5 μg/ml; Sigma) was carefully added in 249 μL of 49 
complete media and samples were incubated for a further 14 hours. Final 50 
concentrations of peptide were 1 μg/mL per peptide for each pool. Staphylococcus 51 
enteroxin B (SEB) (Sigma) was dissolved in DMSO and used at 1 μg/ml (final 52 
concentration) as positive stimulation control, 2 μL DMSO alone was added as a 53 
negative control. 54 
 55 
Antibodies and cell staining  56 
At the end of PBMC stimulation 100 μL EDTA buffer (20 mM in wash buffer containing 57 
PBS with 0.5% bovine serum albumin, 0.1% sodium azide, Sigma) was added to each 58 
tube. Tubes were vortexed and then incubated for 10 min at 37°C. After spinning at 59 
400g for 8 min at 4°C, cells were washed with wash buffer. Pellets were carefully 60 
resuspended before staining antibodies were added and tubes incubated (30 minutes at 61 
4°C). Cells were then washed, lysed with FACS Lysing solution (BD) and permeabilized 62 
with BD Permeabilizing 2 solution (BD) according to the manufacturer's instructions.  63 
Cells were stained intracellularly, following the same steps as for surface staining. 64 
Following a final wash cells were resuspended and fixed in PBS containing 0.5% 65 
paraformaldehyde (Sigma) prior to acquisition on an LSRII flow cytometer using 66 
FACSdiva 6.1 software (BD). 67 
 68 
Absolute T-cell counts 69 
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In order to obtain absolute T-cell counts, 100 μl of fresh whole blood (EDTA-anti-70 
coagulated) was stained with CD45 PerCP and CD3 Qdot605 (all from BioLegend) for 71 
30 min at 4°C, prior to adding 1 ml of FACS lysing solution (BD) and incubating for 10 72 
min according to the manufacturer’s instructions. Then 3 ml of wash buffer were added, 73 
samples were centrifuged, and aquired on an LSR II flow-cytometer (BD).  74 
White blood cells were selected according to CD45 expression on a side scatter versus 75 
CD45 plot. The percentage of CD3 T-cells among white blood cells was determined on 76 
a side scatter versus CD3 plot. The absolute CD3 T-cell count was determined by 77 
multiplying this percentage with the absolute white blood cell count (cells/nL). In order to 78 
determine absolute CD4 and CD8 T-cell counts the absolute CD3 T-cell count (cells/nl) 79 
was multiplied with CD4 and CD8 T-cell percentages.  80 
 81 
T-cell Polyfunctionality 82 
The polyfunctionality index (PI) algorithm was obtained from ‘FunkyCells ToolBox’ 83 
version 0.1.0 beta (www.FunkyCells.com). To calculate the PI, each subset defined by a 84 
given number of displayed functions has a weight assigned which is then multiplied with 85 
the subset frequency. The PI is the sum of these products (PI = where Fi is 86 
the frequency of cells performing i simultaneous functions, q is the polyfunctionality 87 
parameter determining the weight of the subsets, n is the number of possible functions). 88 
The polyfunctionality parameter q was set to 1 as previously described [15]. Samples 89 
containing less than 0.1% activated events were not included in correlations of PI and 90 
other parameters. 91 
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Supplementary Tables 93 
 94 
Supplementary Table S1. CMV- participant demographics 95 
Parameter  ‘young’  ‘older’ 
Total number 29 62 
Age range (mean ± STD) 20 – 34 
(25.5±4.7) 
60 – 85 
(72.2±8.2) 
Females 18 (62 %) 28 (45 %) 
Males 11 (38 %) 34 (55 %) 
White (British or other 
Europeana) 
29 (100%) 62 (100 %) 
a Other European: 1 young adult from Greece and 1 young adult from Switzerland.  96 
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Supplementary Figure Legends 98 
 99 
Supplementary Fig. S1: Gating strategy for T-cell activation markers.  100 
(1) Lymphocytes were gated on an FSC-A versus SSC-A plot. (2) Single cells were 101 
gated on an FSC-H versus FSC-A plot. (3) Dead cells were excluded using a viability 102 
dye in the violet 3 channel. (4) T-cells were first selected on a CD3 versus CD8 plot, 103 
allowing for some CD3 down-regulation on activated CD8+ events (‘CD3_8’). (5) CD3 T-104 
cells were also gated alternatively on a CD3 versus CD4 plot, this time allowing for 105 
some CD3 down-regulation on activated CD4+ events (‘CD3_4’). (6) Both CD3 gates 106 
were then combined (logical ‘OR’), so that the final CD3 T-cell gate included a 107 
maximum of activated CD4 and CD8 T cells. (7)-(11) Subsequently, activated CD8 T-108 
cells were gated with respect to each functional parameter (one by one). The same 109 
process was repeated for activated CD4 T-cells. (12) Phenotypic subsets based on the 110 
expression of CD45RA and CD27 were gated on all CD4 or all CD8 T-cells (including 111 
activated and non-activated) and then combined (logical ‘AND’) with the respective 112 
activation marker gates (or gates derived from these). The numbers/frequencies of 113 
activated CD4 or CD8 T-cells for each combination of phenotypic and functional subsets 114 
were computed subsequently. The positive assay control (SEB) was used to ascertain if 115 
the assay had worked (even if individuals were not responding to CMV-antigens), 116 
whereas the negative assay control (unstimulated) was used to estimate (and subtract) 117 
‘background noise’ for each functional subset (subset by subset). 118 
 119 
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Supplementary Fig. S2: Differences between young and older people in terms of 120 
absolute numbers of CMV-specific CD4 and CD8 T-cells are smaller than in terms 121 
of relative numbers. PBMC from CMV+ participants were stimulated over night with 19 122 
CMV protein-derived overlapping peptide-pools. Activated T cells were identified by 123 
flow-cytometry. The presented data is limited to the UK cohort. (A, B) Diagrams show 124 
absolute counts/nL of CD4 and CD8 T-cells displaying at least one activation marker 125 
(combined read out), IFN-, or TNF. Responses are shown to the 19 proteins combined 126 
(left panels) and the most frequently recognized CMV proteins in the UK cohort (A) for 127 
CD4 T-cells with respect to UL83 (middle) and UL55 (right), (B) for CD8 T-cells with 128 
respect to UL83 (middle) (‘pp65’) and UL123 (right) (‘IE-1’). Significant differences at the 129 
p≤0.05 level are indicated. In addition, ‘n.s.’ (not significant) is indicated for those 130 
differences that were significant using relative T-cell counts (frequencies, compare Fig. 131 
3A-B). Note that in order to determine if there is a general increase in CMV-specific T-132 
cell response size between young and older people, the main end-point was the 133 
combined functional read-out (‘at least one marker positive’) in connection with all 19 134 
tested proteins. The significance level was not adjusted for multiple end-points in (A) or 135 
(B). Absolute counts (in cells/nL of blood) of CD4 (C) and CD8 T-cells (D) seem to 136 
diminish in older people. The effect was not significant for CD4 but highly significant for 137 
CD8 T-cells. As a result, in particular for CD8 T-cells, fewer differences between the 138 
age groups were significant compared to when subset sizes were expressed as a 139 
fraction of CD4 or CD8 T-cells (compare Fig. 3A-B). Boxplots show minimum, 140 
maximum, median, interquartile range, and outliers (o). 141 
 142 
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Supplementary Fig. S3: CMV-infection significantly affects memory subset 143 
distributions in the young and older groups. The unstimulated control tube for each 144 
participant was used for the analysis of CD4 and CD8 T-cell distributions across the 145 
canonical memory compartments defined by the expression of CD27 and CD45RA 146 
(CD45RA+/CD27+ = ‘naïve’ or TNA; CD45RA-/CD27+ = ‘central memory’ or TCM; 147 
CD45RA-/CD27- = ‘effector memory’ or TEM; CD45RA+/CD27- = ‘revertant’ or TEMRA). 148 
Data for CMV+ and CMV- individuals are shown. (A) CMV infection per se has a major 149 
impact on memory subset distribution in both young and older people as previously 150 
shown by us and others [27]. Dot-plots show the TNA (upper right quadrant), TCM (lower 151 
right quadrant), TEM (lower left quadrant), and TEMRA (upper left quadrant) compartments. 152 
(B) The effect of CMV-infection on the naïve T-cell pool is only significant in older 153 
people. Interestingly, the effect of CMV infection on the TEMRA (CD27-/CD45RA+) 154 
compartment seems to be stronger in CD4 than CD8 T cells. Boxplots show minimum, 155 
maximum, median, interquartile range, and outliers (o).  156 
 157 
 158 
Supplementary Fig. S4: Proportional memory subset distributions of CMV-159 
specific T-cells are reflected by distributions in absolute counts but differ from 160 
those of all T-cells. (A) In analogy with Fig. 3C-D, the distribution of T-cells across the 161 
memory compartments, TNA, TCM, TEM, and TEMRA is shown for each age group. 162 
However, instead of frequencies of CD4 or CD8 T-cells, the diagram shows the 163 
proportions that each subset contributes to the whole response (normalized). (B) In 164 
analogy to Fig. 3C-D, the memory subset distributions of CMV-specific CD4 and CD8 T-165 
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cell were analyzed in terms of absolute T-cell counts (limited to the young and older 166 
groups). In each individual and with respect to each CMV-peptide pool, the percentages 167 
of CD4 and CD8 T-cells in the TNA, TCM, TEM, and TEMRA memory compartments were 168 
added up to provide a total response for each memory compartment. These 169 
percentages were multiplied with the absolute CD4 and CD8 T-cell counts in cells/nL. 170 
Differences between the age groups by and large reflect the distributions observed in 171 
terms of fractions of CD4 and CD8 T-cells. (C) The unstimulated control tube was used 172 
for the analysis of memory subsets for all T-cells (CMV-specific and non-CMV-specific) 173 
in CMV+ people across all three age groups. Boxplots show minimum, maximum, 174 
median, interquartile range, outliers (o), and extreme values (*).  175 
 176 
Supplementary Fig. S5: Polyfunctionality varies between CMV-specific T-cell 177 
memory subsets and is generally highest in TEM. The polyfunctionality index (PI) 178 
captures functional subset distributions by weighting the number of functions as well as 179 
subset size. For the shown analysis a linear relationship between the number of 180 
functions and the relative weight of a subset was selected (e.g. subsets with two 181 
functions were assigned twice the weight of subsets with one function, subsets with 182 
three functions were assigned three times the weight of subsets with one function, etc.). 183 
Polyfunctionality is highest in effector memory T-cells, overall similar in young and older 184 
but reduced in the oldest old, where, however, it appears to be increased in naïve CD8 185 
T-cells. Boxplots show minimum, maximum, median, interquartile range, outliers (“o”), 186 
and extreme values (“*”). 187 
 188 
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